U01 CA253472/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2019	1
2020	1
2022	8
2023	5
2024	1

1

Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.

Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Labrie M, et al. Nat Rev Cancer. 2022 Jun;22(6):323-339. doi: 10.1038/s41568-022-00454-5. Epub 2022 Mar 9. Nat Rev Cancer. 2022. PMID: 35264777 Free PMC article. Review.

2

Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma.

Zhou Z, Chen MM, Luo Y, Mojumdar K, Peng X, Chen H, Kumar SV, Akbani R, Lu Y, Liang H. Zhou Z, et al. Cancer Cell. 2022 Nov 14;40(11):1324-1340.e8. doi: 10.1016/j.ccell.2022.10.012. Epub 2022 Nov 3. Cancer Cell. 2022. PMID: 36332624 Free PMC article.

3

Single-cell dissection of tumor microenvironmental response and resistance to cancer therapy.

Luo Y, Liang H. Luo Y, et al. Trends Genet. 2023 Oct;39(10):758-772. doi: 10.1016/j.tig.2023.07.005. Epub 2023 Aug 30. Trends Genet. 2023. PMID: 37658004 Review.

4

Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.

Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F. Kinose Y, et al. Res Sq [Preprint]. 2023 Sep 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1. Res Sq. 2023. PMID: 37841875 Free PMC article. Preprint.

5

A multiplex implantable microdevice assay identifies synergistic combinations of cancer immunotherapies and conventional drugs.

Tatarova Z, Blumberg DC, Korkola JE, Heiser LM, Muschler JL, Schedin PJ, Ahn SW, Mills GB, Coussens LM, Jonas O, Gray JW. Tatarova Z, et al. Nat Biotechnol. 2022 Dec;40(12):1823-1833. doi: 10.1038/s41587-022-01379-y. Epub 2022 Jul 4. Nat Biotechnol. 2022. PMID: 35788566 Free PMC article.

6

Cancer Cells Employ the Most Prolific RNA Editors: A Closer Look at the Single-Cell Level.

Luo Y, Liang H. Luo Y, et al. Cancer Res. 2023 Feb 3;83(3):351-353. doi: 10.1158/0008-5472.CAN-22-3537. Cancer Res. 2023. PMID: 36734079

7

Irreversible HER2 inhibitors overcome resistance to the RSL3 ferroptosis inducer in non-HER2 amplified luminal breast cancer.

Park SY, Jeong KJ, Poire A, Zhang D, Tsang YH, Blucher AS, Mills GB. Park SY, et al. Cell Death Dis. 2023 Aug 18;14(8):532. doi: 10.1038/s41419-023-06042-1. Cell Death Dis. 2023. PMID: 37596261 Free PMC article.

8

Precision Combination Therapies Based on Recurrent Oncogenic Coalterations.

Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Li X, et al. Cancer Discov. 2022 Jun 2;12(6):1542-1559. doi: 10.1158/2159-8290.CD-21-0832. Cancer Discov. 2022. PMID: 35412613 Free PMC article.

9

Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.

Cathcart AM, Smith H, Labrie M, Mills GB. Cathcart AM, et al. Expert Rev Proteomics. 2022 Feb;19(2):115-129. doi: 10.1080/14789450.2022.2070065. Epub 2022 Apr 27. Expert Rev Proteomics. 2022. PMID: 35466854 Free PMC article. Review.

10

Mapping the functional interactions at the tumor-immune checkpoint interface.

Bozorgui B, Kong EK, Luna A, Korkut A. Bozorgui B, et al. Commun Biol. 2023 Apr 27;6(1):462. doi: 10.1038/s42003-023-04777-3. Commun Biol. 2023. PMID: 37106127 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

15 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year